---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004104"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:26:57.458960+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics reports FY2022 net loss $20.3M; cash $18.1M; CPRIT grant $17.6M

## Summary
- Net loss $20.3M ($0.77/share) vs $13.4M ($1.11/share) in FY2021; operating expenses $19.9M.
- Cash $18.1M at Dec 31, 2022; with grants and capital sources, expects funding through 2025.
- Awarded $17.6M CPRIT grant for rhenium obisbemeda leptomeningeal metastases trial.
- Enrolled first patient in ReSPECT-GBM Phase 2b; completed second cohort in ReSPECT-LM Phase 1.
- Grant revenue $224k from CPRIT; received first ~$1.9M in Q4 2022.

## SEC filing metadata
- accession: 0000950170-23-004104
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017023004104/0000950170-23-004104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017023004104/pstv-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004104
- JSON: https://secwatch.observer/filing/0000950170-23-004104.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004104.txt

## Key facts
- Earnings Releases
  PLUS THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2022 results: net income $20.3 million, EPS $(0.77) per share.
  - Period: the fourth quarter and year ended December 31, 2022
  - Net income: $20.3 million
  - EPS: $(0.77) per share
  - Result: reported results
  source text: Net loss for full year 2022 was $20.3 million, or $(0.77) per share, compared to a net loss of $13.4 million, or $(1.11) per share, for full year 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017023004104/0000950170-23-004104-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.